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The enhanced stimulation and outﬂow of catecholamines
has long been recognized as an important mechanism in
the progression of heart failure (1). In 1984, Cohn et al. (2)
established that higher plasma concentrations of norepi-
nephrine predicted worse survival in patients with heart
failure. These studies and others led to the initial clinical
trials to block catecholamines from binding to b-adrenergic
receptors (b-AR) in the heart (3). A promising small
molecule that inhibits the b-adrenergic signaling cascade in
the heart and decreases circulating catecholamines in a pre-
clinical model is presented in the Journal this week from
Kamal and colleagues (4).See page 2549Norepinephrine binds to the b-ARs in the heart and
increases contraction (5). In heart failure, the persistent
catecholamine-mediated activation of b-ARs leads to re-
ceptor phosphorylation, desensitization, and down-
regulation (5). Phosphorylation of the b-ARs is mediated
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is recruited to the b-ARs in the plasma membrane via
activated G-protein bg (Gbg) subunits (6). Blockade of
GRK2 is cardioprotective in pre-clinical models (5). A
peptide encoding the 194–amino acid domain of GRK2,
named bARKct (GRK2 is also known as bARK1), blocks
GRK2, and improves cardiac function in larger animals
and inhibits the progression of cardiac failure in mice (5).
The study from Kamal and et al. (4) also targets GRK2,
and appears to have additional inﬂuence on lowering cate-
cholamine levels.
Chidsey, Braunwald, and Morrow were the ﬁrst to pub-
lish that norepinephrine excretion in the urine was elevated
in patients with heart failure (7). The medullary chromafﬁn
cells in the adrenal glands release catecholamines (norepi-
nephrine and epinephrine). Pioneering work from Esler
provided evidence that in healthy individuals approximately
30% of the norepinephrine in the plasma comes from nerves
in the lungs, 25% from the nerves in the kidneys, 20% to
25% from nerves in skeletal muscle, 5% to 7% from the
hepatomesenteric circulation, 6% from the skin, 4% from the
brain, 3% from the heart, and 2% to 3% from the adrenal
medulla (8). Norepinephrine originating from these tissues
is referred to as spillover, or overﬂow. Overﬂow of norepi-
nephrine (that which is not taken up by neurons, extra-
neuronal sites, or metabolized) is released into the venous
outﬂow. The precise origin(s) of norepinephrine spillover in
heart failure remains a mystery; however, spillover has been
identiﬁed in the heart, kidneys, and skeletal muscle (9–11).
Reduced clearance of catecholamines due to the decrease in
cardiac output also contributes to the increase in plasma
catecholamines in patients with heart failure (1). A signiﬁ-
cant increase is also seen in the adrenal gland activity in
patients with heart failure (9,12).
Excessive norepinephrine is directly toxic to the heart and
is believed to be central to the neurohormonal hypothesis
that exuberant sympathetic activity drives at least part of the
pathophysiology of chronic heart failure. Strategies to reduce
sympathetic overproduction by pharmacologically activating
central a2-adrenergic receptors (a2-AR) or imidazolidine-1
receptors have been tested in patients with heart failure.
Moxonidine, a selective imidazolidine-1 receptor activator,
strikingly lowers plasma sympathetic activity in heart failure,
but had an adverse mortality effect in patients with heart
failure (13). Clearly, signiﬁcantly reducing sympathetic ac-
tivity in heart failure is not by itself successful, but how one
reduces sympathetic drive may be highly important.
Norepinephrine and epinephrine release from the adrenal
gland is regulated through a feedback inhibition loop
that involves phosphorylation of the a2-AR (14). In 2007,
Lymperopoulos et al. showed evidence that this feedback
inhibition loop to decrease the release of norepinephrine
was dysregulated in pre-clinical models of heart failure (15).
Speciﬁcally, this discovery showed that GRK2 up-regulation
in the adrenal gland was the mechanism responsible
for phosphorylating and desensitizing the a2-AR, thereby
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sympathetic overdrive in heart failure.
In this week’s issue of the Journal, Kamal et al. (4)
used a novel small molecule that inhibits GRK2 by bind-
ing to a speciﬁc protein–protein interaction domain of
GRK2 that binds Gbg (4). This small molecule, gallein, was
identiﬁed through a novel compound screen (16). Gallein
was administered daily 4 weeks after transverse aortic
constriction in mice (a pressure overload model) and
continued for 8 weeks. Gallein improved survival, enhanced
cardiac function, and inhibited cardiac hypertrophy (4). In
the heart, gallein restored b-AR density and decreased
GRK2 expression (4). In the circulation, gallein reduced
plasma epinephrine and norepinephrine concentrations (4).
Adrenal glands from transverse aortic constriction mice
treated with gallein and cultured in vitro showed lower
levels of basal catecholamine secretion (4). It is not clear
from these studies what fraction of the circulating cate-
cholamine concentration that is being reduced by gallein is
from the adrenal glands (4). a2-ARs are also expressed in
presynaptic sympathetic nerve terminals; therefore, it is
conceivable that these receptors are also targeted by gallein.
Of note, the density of a2-ARs in the central nervous
system is an order of magnitude higher than those in the
adrenal chromafﬁn cells (17). Future studies may need to
address this issue.
It should be remembered that cardiac myocyte mem-
brane b-AR desensitization and down-regulation are
highly conserved natural mechanisms that may protect the
heart from excessive catecholamine stimulation. If gallein
reduces circulating plasma catecholamines while simulta-
neously restoring cardiac membrane b-AR density, then
this strategy may in principle improve the inotropic state.
Additional studies will eventually be necessary to inves-
tigate this further.
Currently, b-blockers are a mainstay of heart failure
therapy and have proven efﬁcacy to reduce mortality and
morbidity in heart failure (3). The report by Kamal et al.
(4) suggests that a new small molecule targeting GRK2
may have additional beneﬁcial actions in the adrenal gland
and possibly on inhibition of inﬂammation. However,
obstacles remain. GRK2 is ubiquitously expressed, and
gallein might have several off-target effects (i.e., the
brain), leading to unforeseen outcomes not observed in
the relatively short-term treatment in the current study.
The cross-disciplinary team of Smrcka and Blaxall are
leaders in the ﬁeld and a tour de force in small molecule
screening and b-adrenergic signaling. We look forward
to additional pre-clinical and clinical replication from
this group and others.Reprint requests and correspondence: Dr. Jennifer L. Hall,
Lilliehei Heart Institute, Department of Medicine, University
of Minnesota, Cancer and Cardiovascular Research Building,
2231 6th Street SE, Minneapolis, Minnesota 55455. E-mail:
jlhall@umn.edu.
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